Safety/Tolerability and Pharmacokinetic Study of SID142

NCT02625714 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Arterial Occlusive Diseases

Interventions

DRUG: Renexin®
DRUG: SID142

Sponsor

SK Chemicals Co., Ltd.